MUC4 potentiates invasion and metastasis of pancreatic cancer cells through stabilization of fibroblast growth factor receptor 1

Carcinogenesis

Volumn 33, Issue 10, 2012, Pages 1953-1964

  Rachagani, Satyanarayana ^a   Macha, Muzafar A ^a   Ponnusamy, Moorthy P ^a   Haridas, Dhanya ^a   Kaur, Sukhwinder ^a   Jain, Maneesh ^a   Batra, Surinder K ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 9; CYTOKERATIN 18; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FOCAL ADHESION KINASE; GELATINASE B; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; MUCIN 4; NERVE CELL ADHESION MOLECULE; OCCLUDIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN C JUN; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR ZEB1; UVOMORULIN; VIMENTIN;

ACTIN FILAMENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INCIDENCE; CARCINOGENESIS; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; DOWN REGULATION; ENZYME INACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE SILENCING; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREAS METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; CADHERINS; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; GENE KNOCKDOWN TECHNIQUES; HUMANS; MICE; MICE, NUDE; MUCIN-4; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RNA, SMALL INTERFERING; TRANSPLANTATION, HETEROLOGOUS; UP-REGULATION;

EID: 84867311798     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs225     Document Type: Article

References (53)

1. American Cancer Society. (2010) Cancer Facts & Figures 2010. American Cancer Society, Atlanta. The top 5 cancer killers are (in order): lung, colon, breast, pancreatic, and prostate.
2. Jemal, A. et al. (2009) Cancer statistics, 2009. CA Cancer J.Clin., 59, 225-249.
3. Heinemann, V. et al. (2008) Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer, 8:82.
4. Sultana, A. et al. (2008) Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses.Br. J. Cancer, 99, 6-13.
5. Matsuno, S. et al. (2004) Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas, 28, 219-230.
6. Mehlen, P. et al. (2006) Metastasis: a question of life or death. Nat. Rev. Cancer, 6, 449-458.
7. Polyak, K. et al. (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer, 9, 265-273.
8. Thiery, J.P. (2002) Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer, 2, 442-454.
9. Ngan, C.Y. et al. (2007) Quantitative evaluation of vimentin expression in tumour stroma of colorectal cancer. Br. J. Cancer, 96, 986-992.
10. Kowalski, P.J. et al. (2003) E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res., 5, R217-R222.
11. Peinado, H. et al. (2007) Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat. Rev. Cancer, 7, 415-428.
12. Carraway, K.L. et al. (2001) Muc4/sialomucin complex in the mammary gland and breast cancer. J. Mammary Gland Biol. Neoplasia, 6, 323-337.
13. Chauhan, S.C. et al. (2006) Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125). Mod. Pathol., 19, 1386-1394.
14. Handra-Luca, A. et al. (2005) MUC1, MUC2, MUC4, and MUC5AC expression in salivary gland mucoepidermoid carcinoma: diagnostic and prognostic implications. Am. J. Surg. Pathol., 29, 881-889.
15. Hollingsworth, M.A. et al. (2004) Mucins in cancer: protection and control of the cell surface. Nat. Rev. Cancer, 4, 45-60.
16. Llinares, K. et al. (2004) Diagnostic value of MUC4 immunostaining in distinguishing epithelial mesothelioma and lung adenocarcinoma. Mod. Pathol., 17, 150-157.
17. Rakha, E.A. et al. (2005) Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod. Pathol., 18, 1295-1304.
18. Tsutsumida, H. et al. (2007) MUC4 expression correlates with poor prognosis in small-sized lung adenocarcinoma. Lung Cancer, 55, 195-203.
19. Park, H.U. et al. (2003) Aberrant expression of MUC3 and MUC4 membrane-associated mucins and sialyl Le(x) antigen in pancreatic intraepithelial neoplasia. Pancreas, 26, e48-e54.
20. Swartz, M.J. et al. (2002) MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. Am. J. Clin. Pathol., 117, 791-796.
21. Andrianifahanana, M. et al. (2001) Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance. Clin. Cancer Res., 7, 4033-4040.
22. Chaturvedi, P. et al. (2008) MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells. Cancer Res., 68, 2065-2070.
23. Zhu, Y. et al. (2010) The increase in the expression and hypomethylation of MUC4 gene with the progression of pancreatic ductal adenocarcinoma. Med. Oncol., 28 (suppl 1), S175-S184.
24. Bafna, S. et al. (2008) MUC4, a multifunctional transmembrane glycoprotein, induces oncogenic transformation of NIH3T3 mouse fibroblast cells. Cancer Res., 68, 9231-9238.
25. Chaturvedi, P. et al. (2007) MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins. Mol. Cancer Res., 5, 309-320.
26. Moniaux, N. et al. (2007) Human MUC4 mucin induces ultra-structural changes and tumorigenicity in pancreatic cancer cells. Br. J. Cancer., 97, 345-357.
27. Singh, A.P. et al. (2004) Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis. Cancer Res., 64, 622-630.
28. Ponnusamy, M.P. et al. (2008) MUC4 activates HER2 signalling and enhances the motility of human ovarian cancer cells. Br. J. Cancer, 99, 520-526.
29. Moniaux, N. et al. (2004) Generation and characterization of anti-MUC4 monoclonal antibodies reactive with normal and cancer cells in humans. J. Histochem. Cytochem., 52, 253-261.
30. Rachagani, S. et al. (2011) Activated KrasG(1)(2)D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin. Br. J. Cancer, 104, 1038-1048.
31. Ponnusamy, M.P. et al. (2010) MUC4 mucin-induced epithelial to mesenchymal transition: a novel mechanism for metastasis of human ovarian cancer cells. Oncogene, 29, 5741-5754.
32. Nakajima, S. et al. (2004) N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma. Clin. Cancer Res., 10, 4125-4133.
33. Shintani, Y. et al. (2008) Collagen I-mediated up-regulation of N-cadherin requires cooperative signals from integrins and discoidin domain receptor J. Cell Biol., 180, 1277-1289.
34. Hao, L. et al. (2012) Cadherin switch from E- to N-cadherin in melanoma progression is regulated by the PI3K/PTEN pathway through Twist and Snail. Br. J. Dermatol., 166, 1184-1197.
35. Ishiwata, T. et al. (1998) Characterization of keratinocyte growth factor and receptor expression in human pancreatic cancer. Am. J. Pathol., 153, 213-222.
36. Kobrin, M.S. et al. (1993) Aberrant expression of type I fibroblast growth factor receptor in human pancreatic adenocarcinomas. Cancer Res., 53, 4741-4744.
37. Liu, Z. et al. (2007) Identification of a fibroblast growth factor receptor 1 splice variant that inhibits pancreatic cancer cell growth. Cancer Res., 67, 2712-2719.
38. Taeger, J. et al. (2011) Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer. Mol. Cancer Ther., 10, 2157-2167.
39. Suyama, K. et al. (2002) A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor. Cancer Cell, 2, 301-314.
40. Cavallaro, U. et al. (2001) N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor signalling. Nat. Cell Biol., 3, 650-657.
41. Peluso, J.J. (2000) N-cadherin-mediated cell contact regulates ovarian surface epithelial cell survival. Biol. Signals Recept., 9, 115-121.
42. Kalluri, R. et al. (2009) The basics of epithelial-mesenchymal transition. J. Clin. Invest., 119, 1420-1428.
43. Kalluri, R. (2009) EMT: when epithelial cells decide to become mesenchymal-like cells. J. Clin. Invest., 119, 1417-1419.
44. Voulgari, A. et al. (2009) Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim. Biophys. Acta., 1796, 75-90.
45. Christofori, G. et al. (1999) The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem. Sci., 24, 73-76.
46. Takeichi, M. (1995) Morphogenetic roles of classic cadherins. Curr. Opin. Cell Biol., 7, 619-627.
47. Fridman, R. et al. (2003) Cell surface association of matrix metalloproteinase-9 (gelatinase B). Cancer Metastasis Rev., 22, 153-166.
48. Stockinger, A. et al. (2001) E-cadherin regulates cell growth by modulating proliferation-dependent beta-catenin transcriptional activity. J. Cell Biol., 154, 1185-1196.
49. Valdes, F. et al. (2002) The epithelial mesenchymal transition confers resistance to the apoptotic effects of transforming growth factor Beta in fetal rat hepatocytes. Mol. Cancer Res., 1, 68-78.
50. Yang, J. et al. (2004) Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell, 117, 927-939.
51. Gravdal, K. et al. (2007) A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin. Cancer Res., 13, 7003-7011.
52. Maeda, M. et al. (2005) Cadherin switching: essential for behavioral but not morphological changes during an epithelium-to-mesenchyme transition. J. Cell Sci., 118, 873-887.
53. Downward, J. (2004) PI 3-kinase, Akt and cell survival. Semin. Cell Dev. Biol., 15, 177-182.